var data={"title":"Gonadorelin acetate (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gonadorelin acetate (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6278?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gonadorelin-acetate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gonadorelin acetate (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177038\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lutrepulse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177075\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gonadotropin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177042\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Primary hypothalamic amenorrhea:</b> Females: IV, SubQ.: Initial dose: 5 mcg every 90 minutes via suitable pulsatile pump. Dosage adjustments may be made every 21 days if necessary.  An increase in dosage may be necessary if no response after 3 treatment intervals. In clinical trials, doses of 1-20 mcg were successfully administered. Treatment should be continued for 2 weeks after ovulation to maintain the corpus luteum.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Appropriate vial should be selected for individualized treatment. Typical dose (5 mcg) is delivered with use of 0.8 mg vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11300779\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lutrepulse: 0.8 mg, 3.2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11300326\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177025\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV, SubQ: Lutrepulse vials for IV or SubQ use: Following reconstitution, administer IV or SubQ using a suitable pulsatile pump. Set the pump to deliver 25 or 50 mcL of solution, based upon the dose required and vial strength used. When using the 0.8 mg vial, the pump can be set to deliver a dose of 2.5 mcg (25 mcL) per pulse or 5 mcg (50 mcL) per pulse. When using the 3.2 mg vial, the pump can be set to deliver a dose of 10 mcg (25 mcL) per pulse or 20 mcg (50 mcL) per pulse. Pump should deliver dose over a pulse period of 1 minute and a pulse frequency of 90 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132606\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177024\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Induction of ovulation in females with hypothalamic amenorrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116839\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\"> <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177015\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Superficial thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylactic shock, anaphylaxis, antibody development (with long-term therapy, resulting in therapy failure), erythema at injection site, fever, headache, hypermenorrhea, inflammation at injection site (mild and severe), nausea, ovarian hyperstimulation syndrome (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177028\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gonadorelin or any component of the formulation; women with any condition (eg, pituitary prolactinoma) that could be exacerbated by pregnancy; patients who have ovarian cysts; any condition (eg, hormone-dependent tumor) that may be worsened by reproductive hormones </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177013\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported rarely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian cancer: <b>[Canadian Boxed Warning]: Ovarian cancer has been reported in a very small number of infertile women treated with fertility drugs. A causal relationship has not been established.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian hyperstimulation syndrome: <b>[Canadian Boxed Warning]: Ovarian hyperstimulation syndrome (OHSS) is a risk of ovulation induction therapy although it is rare with pulsatile gonadotropin releasing hormone (GnRH) therapy. Discontinue therapy if OHSS occurs; spontaneous resolution may be expected.</b> OHSS is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: Therapy should only be conducted by clinicians familiar with infertility problems and their management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple births: May result from the use of these medications; advise patients of the potential risk of multiple births before starting treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299419\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177017\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15998&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11300324\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">The risk of fetal harm appears remote if gonadorelin is used during pregnancy. Clinical studies of pregnant women have not demonstrated an increased risk of fetal abnormalities during the first trimester. Follow-up reports of infants born to exposed mothers revealed no adverse effects or complications attributed to gonadorelin therapy. Based on its indicated use, gonadorelin treatment is continued for 2 weeks following ovulation to maintain the corpus luteum; initiation of treatment is not appropriate if pregnancy has been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11300325\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if gonadorelin is excreted into breast milk. Not indicated for use in nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177021\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ovarian ultrasound at baseline and at least weekly while on therapy or until ovulation is confirmed; LH, FSH, estradiol, progesterone (midluteal phase); basal body temperature; pelvic exam; injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (all daily or as necessary) and liver enzymes (weekly) (SOGC-CFAS 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177012\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates the release of luteinizing hormone (LH) from the anterior pituitary gland</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177027\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Response to therapy usually observed within 2-3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~10-15 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily renal </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~10-40 minutes; increased in patients with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038649\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cryptocur (GR, NL);</li>\n      <li>Gonavet (BD);</li>\n      <li>HRF (BE, GB, IE, LU);</li>\n      <li>Kryptocur (BE, CH, CZ, DE, HN, HR, IT, LU);</li>\n      <li>LH-RH Tanabe (TW);</li>\n      <li>Luforan (BE);</li>\n      <li>Lutamin (JP);</li>\n      <li>Lutrelef (BE, CH, FR, HU, PL, SE, SG);</li>\n      <li>Relefact (CZ, GR, IE);</li>\n      <li>Relefact LH-RH (AT, KR, NL);</li>\n      <li>Relisorm L (BR, HU);</li>\n      <li>Wyeth-Ayerst HRF (AU);</li>\n      <li>Zyklomat (MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/25574681/pubmed\" target=\"_blank\" id=\"25574681\">25574681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/22531097/pubmed\" target=\"_blank\" id=\"22531097\">22531097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joint Society of Obstetricians and Gynaecologists of Canada-Canadian Fertility and Andrology Society (SOGC-CFAS) Clinical Practice Guidelines Committee, Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. <i>Int J Gynaecol Obstet</i>. 2012;116(3):268-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/22416285/pubmed\" target=\"_blank\" id=\"22416285\">22416285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kesrouani A, Abdallah MA, Attieh E, Abboud J, Atallah D, Makhoul C. Gonadotropin-releasing hormone for infertility in women with primary hypothalamic amenorrhea. Toward a more-interventional approach. <i>J Reprod Med</i>. 2001;46(1):23-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/11209627/pubmed\" target=\"_blank\" id=\"11209627\">11209627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lutrepulse (gonadorelin acetate) [product monograph]. North York, Ontario, Canada: Ferring Inc; August 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/27678032/pubmed\" target=\"_blank\" id=\"27678032\">27678032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15998 Version 66.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F177038\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F177075\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F177042\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F11300779\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11300326\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F177025\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132606\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F177024\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26116839\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F177015\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F177028\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F177013\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299419\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F177017\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11300324\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11300325\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F177021\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F177012\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F177027\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038649\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/15998|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gonadorelin-acetate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Gonadorelin acetate (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}